Last reviewed · How we verify
HRS-9813 Capsule
HRS-9813 is a novel small molecule being developed by Guangdong Hengrui Pharmaceutical for pulmonary fibrosis. Currently in Phase II trials, it aims to address unmet needs in this chronic condition. The drug has shown promising safety and efficacy profiles in early studies.
At a glance
| Generic name | HRS-9813 Capsule |
|---|---|
| Sponsor | Guangdong Hengrui Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-9813 Capsule CI brief — competitive landscape report
- HRS-9813 Capsule updates RSS · CI watch RSS
- Guangdong Hengrui Pharmaceutical Co., Ltd portfolio CI